Yazar "Balca B.P." seçeneğine göre listele

Listeleniyor 1 - 1 / 1
  • Küçük Resim Yok
    Öğe
    Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort demographic, clinical, and laboratory features
    (Lippincott Williams and Wilkins, 2015) Altintas A.; Karabudak R.; Balca B.P.; Terzi M.; Soysal A.; Saip S.; Kurne A.T.; Uygunoglu U.; Nalbantoglu M.; Celik G.G.; Isik N.; Celik Y.; Gokcay F.; Duman T.; Boz C.; Yucesan C.; Mangan M.S.; Celebisoy N.; Diker S.; Isikay I.C.; Kansu T.; Siva A.
    Background: Neuromyelitis optica (NMO) is an immune-mediated, chronic relapsing, inflammatory disease characterized by severe attacks of optic neuritis and myelitis. Objective: To determine the demographic, clinical, and laboratory features; antibody status; and treatment modalities of patients with NMO and neuromyelitis optica spectrum disorders in a Turkish cohort from 11 centers. Methods: A total of 182 patients were included in this study. Data on age at disease onset, sex, type of attacks, clinical presentation, analysis of cerebrospinal fluid, serum antiaquaporin-4 antibody status, annual progression index, and medical and family histories were collected. Results: Mean age was 38.43 ± 12.40 years (range, 13 to 75 y), and mean age at disease onset was 31.29 ± 12.40 years (median, 29 y; range, 10 to 74 y). In NMO group, the rate of NMO immunoglobulin (Ig)G positivity was 62.5%. The annual progression index was significantly higher in the longitudinally extending spinal cord lesion. The mean Expanded Disability Status Scale score was higher in the late than early-onset NMO group. Conclusion: Our results revealed a lower rate of NMO IgG positivity, more severe disability in patients with NMO/neuromyelitis optica spectrum disorders presenting with either transverse myelitis or lateonset NMO, and no correlation between disability and NMO IgG status. © 2015 Wolters Kluwer Health, Inc. All rights reserved.